BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 7970942)

  • 21. [Problems in measuring parameters of the fibrinolytic system: circadian rhythm of tissue-type plasminogen activator and plasminogen activator inhibitor].
    Köhler M; Miyashita C
    Klin Wochenschr; 1988; 66 Suppl 12():62-7. PubMed ID: 3126347
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Behaviour of tissue plasminogen activator, plasminogen activator inhibitor 1 and their complex in various disease states.
    Niwano H; Takahashi H; Tatewaki W; Wada K; Seki Y; Shibata A
    Blood Coagul Fibrinolysis; 1992 Aug; 3(4):389-93. PubMed ID: 1420814
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impaired fibrinolysis in the hemolytic-uremic syndrome of childhood.
    Menzel D; Levi M; Dooijewaard G; Peters M; ten Cate JW
    Ann Hematol; 1994 Jan; 68(1):43-8. PubMed ID: 8110878
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Secretory response of the vessel wall to DDAVP and venous occlusion in von Willebrand's disease.
    Bykowska K; Letowska M; Sabliński J; Binder BR; Kopeć M; Lopaciuk S
    Acta Haematol Pol; 1994; 25(3):261-8. PubMed ID: 7992599
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Imbalance of plasminogen activator inhibitor type-1 (PAI-1) and tissue plasminogen activator (t-PA) activity in patients with Noonan syndrome.
    Mehta P; Parker RI
    J Pediatr Hematol Oncol; 2010 Oct; 32(7):532-6. PubMed ID: 20686427
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Platelet hyperactivation in patients with essential thrombocythemia is not associated with vascular endothelial cell damage as judged by the level of plasma thrombomodulin, protein S, PAI-1, t-PA and vWF.
    Bellucci S; Ignatova E; Jaillet N; Boffa MC
    Thromb Haemost; 1993 Nov; 70(5):736-42. PubMed ID: 8128427
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Value of coagulation function and fibrinolytic system assessment in patients with gestational diabetes mellitus].
    Liu BY; Jian YL; Zhong M; Yu YH; Wang Q; Zhang J
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 Jan; 27(1):35-7. PubMed ID: 17259140
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stimulation of tissue-type plasminogen activator synthesis by retinoids in cultured human endothelial cells and rat tissues in vivo.
    Kooistra T; Opdenberg JP; Toet K; Hendriks HF; van den Hoogen RM; Emeis JJ
    Thromb Haemost; 1991 May; 65(5):565-72. PubMed ID: 1908141
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hyperfibrinolysis in alcoholic cirrhosis: relative plasminogen activator inhibitor type 1 deficiency.
    Ferguson JW; Helmy A; Ludlam C; Webb DJ; Hayes PC; Newby DC
    Thromb Res; 2008; 121(5):675-80. PubMed ID: 17870147
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis--study in healthy subjects and correlation with blood fibrinolytic parameters.
    Colucci M; Scopece S; Gelato AV; Dimonte D; Semeraro N
    Thromb Haemost; 1997 Apr; 77(4):725-9. PubMed ID: 9134650
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Renal and hepatic handling of endogenous tissue-type plasminogen activator (t-PA) and its inhibitor in man.
    Brommer EJ; Derkx FH; Schalekamp MA; Dooijewaard G; vd Klaauw MM
    Thromb Haemost; 1988 Jun; 59(3):404-11. PubMed ID: 3142078
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes.
    Rość D; Kremplewska-Nalezyta E; Gadomska G; Zastawna E; Michalski A; Drewniak W
    Med Sci Monit; 2000; 6(4):684-91. PubMed ID: 11208392
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fibrinolytic activity in peripheral atherosclerosis in the elderly.
    van der Bom JG; Bots ML; Haverkate F; Meyer P; Hofman A; Grobbee DE; Kluft C
    Thromb Haemost; 1999 Feb; 81(2):275-80. PubMed ID: 10064006
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Type 2 diabetes: assessment of endothelial lesion and fibrinolytic system markers.
    Soares AL; Sousa Mde O; Dusse LM; Fernandes AP; Lasmar MC; Novelli BA; Lages Gde F; Carvalho Md
    Blood Coagul Fibrinolysis; 2007 Jul; 18(5):395-9. PubMed ID: 17581312
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Regulation of tissue-type plasminogen activator-mediated fibrinolysis by plasminogen activator inhibitor type-1 in patients with ischaemic heart disease: possible unfavourable effect of diuretics.
    Pedersen OD; Gram J; Bagger H; Keller N; Jespersen J
    Coron Artery Dis; 1994 Jul; 5(7):617-23. PubMed ID: 7952424
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impaired release of tissue plasminogen activator from the endothelium in Graves' disease - indicator of endothelial dysfunction and reduced fibrinolytic capacity.
    Li Y; Chen H; Tan J; Wang X; Liang H; Sun X
    Eur J Clin Invest; 1998 Dec; 28(12):1050-4. PubMed ID: 9893018
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Endothelial damage and activation of the hemostatic system during radiofrequency catheter isolation of pulmonary veins.
    Bulava A; Slavík L; Fiala M; Heinc P; Skvarilova M; Lukl J; Krcová V; Indrák K
    J Interv Card Electrophysiol; 2004 Jun; 10(3):271-9. PubMed ID: 15133367
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Von Willebrand factor and fibrinolytic parameters during the desmopressin test in patients with Cushing's disease.
    Pecori Giraldi F; Ambrogio AG; Fatti LM; Rubini V; Cozzi G; Scacchi M; Federici AB; Cavagnini F
    Br J Clin Pharmacol; 2011 Jan; 71(1):132-6. PubMed ID: 21143510
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fibrinolytic capacity following stimulation with desmopressin acetate in patients with diabetes mellitus.
    Grant MB; Fitzgerald C; Guay C; Lottenberg R
    Metabolism; 1989 Sep; 38(9):901-7. PubMed ID: 2505017
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumor necrosis factor and interleukin-1 induce expression of the verocytotoxin receptor globotriaosylceramide on human endothelial cells: implications for the pathogenesis of the hemolytic uremic syndrome.
    van de Kar NC; Monnens LA; Karmali MA; van Hinsbergh VW
    Blood; 1992 Dec; 80(11):2755-64. PubMed ID: 1333300
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.